86
Participants
Start Date
April 7, 2020
Primary Completion Date
July 29, 2022
Study Completion Date
February 24, 2025
MRTX849
KRAS G12C Inhibitor
TNO155
SHP2 Inhibitor
Local Institution - 002-813, New York
Local Institution - 002-806, New York
Local Institution - 002-811, Novi
Local Institution - 002-810, Milwaukee
Local Institution - 002-828, Chicago
Local Institution - 002-809 A, St Louis
Local Institution - 002-809 C, St Louis
Local Institution - 002-809, St Louis
Local Institution - 002-809 E, St Louis
Local Institution - 002-809 B, Creve Coeur
Local Institution - 002-809 D, City of Saint Peters
Local Institution - 002-942, Wichita
Local Institution - 002-801, San Antonio
Local Institution - 002-805, Los Angeles
Local Institution - 002-803, Orange
Local Institution - 002-804, Boston
Local Institution - 002-808, Boston
Lead Sponsor
Collaborators (1)
Novartis
INDUSTRY
Mirati Therapeutics Inc.
INDUSTRY